Literature DB >> 1731105

Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

M Connors1, A B Kulkarni, P L Collins, C Y Firestone, K L Holmes, H C Morse, B R Murphy.   

Abstract

It was previously demonstrated that the vaccinia virus recombinants expressing the respiratory syncytial virus (RSV) F, G, or M2 (also designated as 22K) protein (Vac-F, Vac-G, or Vac-M2, respectively) induced almost complete resistance to RSV challenge in BALB/c mice. In the present study, we sought to identify the humoral and/or cellular mediators of this resistance. Mice were immunized by infection with a single recombinant vaccinia virus and were subsequently given a monoclonal antibody directed against CD4+ or CD8+ T cells or gamma interferon (IFN-gamma) to cause depletion of effector T cells or IFN-gamma, respectively, at the time of RSV challenge (10 days after immunization). Mice immunized with Vac-F or Vac-G were completely or almost completely resistant to RSV challenge after depletion of both CD4+ and CD8+ T cells prior to challenge, indicating that these cells were not required at the time of virus challenge for expression of resistance to RSV infection induced by the recombinants. In contrast, the high level of protection of mice immunized with Vac-M2 was completely abrogated by depletion of CD8+ T cells, whereas depletion of CD4+ T cells or IFN-gamma resulted in intermediate levels of resistance. These results demonstrate that antibodies are sufficient to mediate the resistance to RSV induced by the F and G proteins, whereas the resistance induced by the M2 protein is mediated primarily by CD8+ T cells, with CD4+ T cells and IFN-gamma also contributing to resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731105      PMCID: PMC240842     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.

Authors:  J A Nicholas; K L Rubino; M E Levely; E G Adams; P L Collins
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

2.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.

Authors:  E J Stott; L A Ball; K K Young; J Furze; G W Wertz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

3.  Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

Authors:  N Elango; G A Prince; B R Murphy; S Venkatesan; R M Chanock; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination.

Authors:  A Wille; A Gessner; H Lother; F Lehmann-Grube
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

5.  Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells.

Authors:  W Allan; Z Tabi; A Cleary; P C Doherty
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

6.  Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice.

Authors:  G W Wertz; E J Stott; K K Young; K Anderson; L A Ball
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

7.  Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells.

Authors:  M J Cannon; E J Stott; G Taylor; B A Askonas
Journal:  Immunology       Date:  1987-09       Impact factor: 7.397

8.  Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen.

Authors:  R M Pemberton; M J Cannon; P J Openshaw; L A Ball; G W Wertz; B A Askonas
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

9.  Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues.

Authors:  Y Kuchino; F Mori; H Kasai; H Inoue; S Iwai; K Miura; E Ohtsuka; S Nishimura
Journal:  Nature       Date:  1987 May 7-13       Impact factor: 49.962

10.  Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus.

Authors:  M J Cannon; P J Openshaw; B A Askonas
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  37 in total

1.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 2.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

3.  Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.

Authors:  Christine Krempl; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

4.  Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.

Authors:  U J Buchholz; H Granzow; K Schuldt; S S Whitehead; B R Murphy; P L Collins
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses.

Authors:  Guillermina A Melendi; Dowd Bridget; Ana C Monsalvo; Federico F Laham; Patricio Acosta; Maria Florencia Delgado; Fernando P Polack; Pablo M Irusta
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

6.  Primary cytotoxic T-cell responses to bovine respiratory syncytial virus in calves.

Authors:  R M Gaddum; R S Cook; L H Thomas; G Taylor
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

7.  Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection.

Authors:  X Zhu; N Venkataprasad; J Ivanyi; H M Vordermeier
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

8.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Authors:  José A Melero; Martin L Moore
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic.

Authors:  Toby M Ward; Vicki Traina-Dorge; Kara A Davis; Wayne L Gray
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.